Preventing TAB1-mediated p38 activation during myocardial infarction

预防心肌梗死期间 TAB1 介导的 p38 激活

• 批准号: G1001138/1
• 负责人: Michael Marber
• 金额: $ 73.09万
• 依托单位: King's College London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2011
• 资助国家: 英国
• 起止时间: 2011 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G1001138%2F1
• 关键词: Preventing; TAB1; mediated; p38; activation

During myocardial infarction an enzyme called p38 becomes activated and worsens the injury suffered by the heart. Although p38 can be inhibited with drugs, and this leads to reduced heart injury, these drugs have caused serious side effects in early clinical trials. This is probably because p38 is a very important enzyme throughout the body. The purpose of this grant is to find a way of inhibiting p38 during myocardial infarction by interfering with the way it becomes activated. The reason why this is attractive is that the activation mechanism during myocardial infarction is very unusual in that it requires p38 to bind another protein called TAB1. Thus interfering with this mechanism should not inhibit p38 activation under other circumstances.

在心肌梗塞期间，一种叫做p38的酶被激活，并修复心脏受到的损伤。虽然p38可以被药物抑制，这导致心脏损伤减少，但这些药物在早期临床试验中引起了严重的副作用。这可能是因为p38是一种非常重要的酶在整个身体。这项资助的目的是找到一种方法，通过干扰p38被激活的方式来抑制心肌梗死期间的p38。这之所以有吸引力，是因为心肌梗死期间的激活机制非常不寻常，因为它需要p38结合另一种称为TAB1的蛋白质。因此，在其他情况下，干扰该机制不应抑制p38活化。